There has been limited research aimed at understanding the cognitive features that predict outcomes in autistic adults. Difficulties in social cognition and executive function (EF) processes have been proposed as important cognitive components underlying social functioning outcomes. In this study, 305 autistic adults were administered a battery of social cognition, EF, and social functioning assessments to determine the degree to which social cognition and EF factors predicted outcomes. For social cognition, hierarchical regressions showed that EF explained neither theory of mind scores nor emotion recognition scores. We then ran several mediation models to determine whether EF explained social functioning independently of social cognition. These exploratory analyses show that poorer performance‐based EF and social cognition both predicted more clinician‐observed social challenges, while poorer self‐reported EF and social cognition predicted more self‐reported social challenges. Effects on outcomes were independent of each other. Our results highlight the potential of bot EF and social cognition measures to provide clinically meaningful markers for social functioning, but via separate pathways. This study supports the utility of targeting EF and social cognition processes in autistic adults in assessment and support pathways.
There is significant interest in the possible influence of chronotype on clinical states in young people with emerging mental disorders. We apply a dynamic approach (bivariate latent change score modelling) to examine the possible prospective influence of chronotype on depressive and hypo/manic symptoms in a youth cohort with predominantly depressive, bipolar, and psychotic disorders (N = 118; 14–30-years), who completed a baseline and follow-up assessment of these constructs (mean interval = 1.8-years). Our primary hypotheses were that greater baseline eveningness would predict increases in depressive but not hypo/manic symptoms. We found moderate to strong autoregressive effects for chronotype (β = -0.447 to −0.448, p < 0.001), depressive (β = -0.650, p < 0.001) and hypo/manic symptoms (β = -0.819, p < 0.001). Against our predictions, baseline chronotypes did not predict change in depressive (β = -0.016, p = 0.810) or hypo/manic symptoms (β = 0.077, p = 0.104). Similarly, the change in chronotype did not correlate with the change in depressive symptoms (β = -0.096, p = 0.295) nor did the change in chronotype and the change in hypo/manic symptoms (β = -0.166, p = 0.070). These data suggest that chronotypes may have low utility for predicting future hypo/manic and depressive symptoms in the short term, or that more frequent assessments over longer periods are needed to observe these associations. Future studies should test whether other circadian phenotypes (e.g. sleep-wake variability) are better indicators of illness course.
TDthe Chronobiology & Chronotherapy Task Force of the International Society for Bipolar Disorders
the Chronobiology & Chronotherapy Task Force of the International Society for Bipolar Disorders
+35
Introduction: Circadian dysfunction is involved in the pathophysiology of bipolar disorders (BD), and circadian‐based interventions are gaining recognition in their management. Moreover, basic and epidemiologic research has generated findings inspiring circadian‐informed self‐ and clinician‐management strategies. Despite these gains, many Clinical Practice Guidelines and clinical training programs have not incorporated this evidence in their recommendations and curricula. This International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force position paper reports a Delphi‐based expert consensus on what is essential for mental health clinicians to know about the chronobiology and chronotherapy of BD. Methods: An initial pool of statements was extracted from academic and grey literature, and experts could suggest additional statements. Statements were rated on a 5‐point scale (‘essential’; ‘important’; ‘don't know/depends’; ‘unimportant’; ‘should not be included’). Consensus was reached when statements were rated as essential or important by ≥ 80% of experts. Results: Thirty experts from 15 countries in Europe, North and South America, and the Asia Pacific participated (mean age of 55.3 years [SD = 11.8]; 40% female; 83% psychiatrists; mean clinical experience of 26 years [SD = 10.8]). Eight‐hundred‐and‐thirty‐seven statements were rated across three rounds. Consensus was reached on 342 statements spanning four major themes: basic circadian science; circadian health and disruption; chronobiology of BD; and six chronotherapies (e.g., protocols, outcomes, risks/contraindications). Conclusions: An expert consensus was obtained on the essential information about the chronobiology and chronotherapy of BD, intended to help clinicians optimise their management of BD. Dissemination of this knowledge is expected to enhance the training and efficacy of clinicians.
A large within-person discrepancy between fluid and crystallised cognition may represent a sensitive cross-sectional proxy for an atypical cognitive trajectory. However, this proxy has not been widely studied in bipolar disorder (BD), and replication data regarding the prevalence and predictors of large discrepancy profiles in BD are therefore lacking. Using a shared analytic pipeline, we analysed cross-sectional cognitive data from 16 independent BD cohorts across 10 countries (n= 3339). Fluid-crystallised discrepancy profiles (FCDPs) were defined as the within-cohort standardised difference between fluid and crystallised cognition. A large (>0.5SD difference) FCDP was taken as a proxy for an atypical cognitive trajectory. We estimated the prevalence of large FCDPs in each cohort and examined sociodemographic and clinical predictors using regression, then compared, synthesised, and meta-analysed the results. In two cohorts with prospective data, we calculated FCDPs in follow up data as well as longitudinal short-term (~1-2 years) fluid cognitive change scores. The pooled prevalence of large FCDPs was 34%, with similar proportions across cohorts despite differences in age, illness duration and clinical features. Clinical course variables showed little or no association with large FCDPs. In the prospective cohorts, large FCDPs were highly stable over ~2 years but largely unrelated to short-term longitudinal cognitive change. Nonetheless, ~20% of participants showed short-term decline, suggesting heterogeneity in how longer-term cognitive deviations and immediate change relate within BD. The pattern of results suggest that a sizeable subgroup of BD shows a meaningful discrepancy between fluid and crystallised cognition that is not readily explained by aging or illness chronicity indicators. The pattern is consistent with either a long-standing neurodevelopmental vulnerability or an early-onset decrement in fluid cognition that then remains relatively stable over time. However, another BD subgroup may still exhibit genuinely progressive cognitive deterioration that is not well captured by the discrepancy-based trajectory proxy.